Search

Your search keyword '"Godart, Jérémy"' showing total 15 results
Start Over Author "Godart, Jérémy"
15 results on '"Godart, Jérémy"'

12. PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System

Author

Corbeau, Anouk, Nout, Remi, Mens, Jan Willem, Horeweg, N, Godart, Jérémy, Kerkhof, E.M., Kuipers, S.C. (Sander), van Poelgeest, M, Kroep, JR, Boere, Ingrid, van Doorn, Lena, Hoogeman, Mischa, van der Heide, UA, Putter, H., Welters, MJP, van der Burg, SH, Creutzberg, CL, de Boer, SM, Radiotherapy, Medical Oncology, and Gynecological Oncology

Subjects
SDG 3 - Good Health and Well-being
Abstract

External beam radiation therapy (EBRT) with concurrent chemotherapy followed by brachytherapy is a very effective treatment for locally advanced cervical cancer (LACC). However, treatment-related toxicity is common and reduces the patient’s quality of life (QoL) and ability to complete treatment or undergo adjuvant therapies. Intensity modulated proton therapy (IMPT) enables a significant dose reduction in organs at risk (OAR), when compared to that of standard intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT). However, clinical studies evaluating whether IMPT consequently reduces side effects for LACC are lacking. The PROTECT trial is a nonrandomized prospective multicenter phase-II-trial comparing clinical outcomes after IMPT or IMRT/VMAT in LACC. Thirty women aged >18 years with a histological diagnosis of LACC will be included in either the IMPT or IMRT/VMAT group. Treatment includes EBRT (45 Gy in 25 fractions of 1.8 Gy), concurrent five weekly cisplatin (40 mg/m2), and 3D image (MRI)-guided adaptive brachytherapy. The primary endpoint is pelvic bones Dmean and mean bowel V15Gy. Secondary endpoints include dosimetric parameters, oncological outcomes, health-related QoL, immune response, safety, and tolerability. This study provides the first data on the potential of IMPT to reduce OAR dose in clinical practice and improve toxicity and QoL for patients with LACC

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results